Clinical Trials · NCT02019706
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Enrollment
- 80
- Start date
- Feb 2014
- Locations
- 1 site, United States
- Primary endpoint
- To determine which imaging technique (F-DOPA PET/CT, 68Ga-DOTATATE PET/CT, CT, and/or MRI) has the best sensitivity.